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ABSTRACT: MicroRNAs (miRs) are small noncoding RNAs that regulate mRNA stability and/or translation. Because of their
release into the circulation and their remarkable stability, miR levels in plasma and other biological ﬂuids can serve as diagnostic
and prognostic disease biomarkers. However, quantifying miRs in the circulation is challenging due to issues with sensitivity and
speciﬁcity. This Letter describes for the ﬁrst time the design and characterization of a regenerative, solid-state localized surface
plasmon resonance (LSPR) sensor based on highly sensitive nanostructures (gold nanoprisms) that obviates the need for labels
or ampliﬁcation of the miRs. Our direct hybridization approach has enabled the detection of subfemtomolar concentration of
miR-X (X = 21 and 10b) in human plasma in pancreatic cancer patients. Our LSPR-based measurements showed that the miR
levels measured directly in patient plasma were at least 2-fold higher than following RNA extraction and quantiﬁcation by reverse
transcriptase-polymerase chain reaction. Through LSPR-based measurements we have shown nearly 4-fold higher concentrations
of miR-10b than miR-21 in plasma of pancreatic cancer patients. We propose that our highly sensitive and selective detection
approach for assaying miRs in plasma can be applied to many cancer types and disease states and should allow a rational
approach for testing the utility of miRs as markers for early disease diagnosis and prognosis, which could allow for the design of
eﬀective individualized therapeutic approaches.
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Pancreatic ductal adenocarcinoma (PDAC)-related deathsare a major health concern in the United States since the
ﬁve-year survival rate is only 6%.1 A crucial contributor to this
dismal statistic is the absence of a biomarker for early PDAC
detection. Moreover, most patients with PDAC do not develop
speciﬁc symptoms until the disease is quite advanced.
Therefore, at clinical presentation, PDAC patients often have
locally advanced and/or metastatic disease, which precludes
eﬀective therapy in the vast majority of patients. In this context
microRNAs (miRs),2 which are small single-stranded, non-
coding RNAs often play a major role in cell proliferation,
survival, migration, invasion, and metastasis in various
cancers,3−5 including PDAC.6,7 Moreover, miRs are released
into the circulation, where they exhibit remarkable stability.
Therefore, the development of sensitive and speciﬁc detection
techniques, which precisely and quantitatively measure the
concentration of miRs in their native environments such as
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blood or plasma, may provide a unique opportunity for
developing diagnostic and prognostic markers in PDAC.6−8
Microarrays9 and quantitative reverse transcription polymer-
ase chain reaction (qRT-PCR)10,11 assays are routinely used to
detect miRs. However, these methods are semiquantitative,
require sequence-based ampliﬁcation and radioactive labeling
steps, and suﬀer from cross-hybridization and invalid internal
controls. Other analytical techniques such as electrochem-
ical12,13 and ﬂuorescence-based assays14 are also used to
quantify the miRs. However, such techniques require either
additional ampliﬁcation or labeling, or complex electron/energy
transfer processes, and cannot be performed in physiological
media. A few label-free techniques such as photonic microring
resonators,15 nanopores,16,17 and nanoparticle-based biobar-
code gel assay18 can detect miRs associated with cancer
patients. However, microring resonators suﬀer from low
sensitivity and do not work in physiological media. Although
nanopore-based sensors have shown the ability to detect miRs
in the circulation of lung cancer patients, the technique requires
a complicated fabrication procedure, a high probe concen-
tration, and a speciﬁc probe signature.16 The biobarcode gel
technique relies on complex sandwich-type capturing methods,
uses of the toxic chemical potassium cyanide, and may not be
applicable to clinically relevant patient samples.
Plasmonic nanostructures have gained signiﬁcant attention
because of their geometrical feature-dependent localized surface
plasmon resonance (LSPR) properties,19−23 which can be
further controlled by modulating their local dielectric environ-
ment.21,24 Utilizing these properties, several molecular25,26 and
biological27−34 sensors have been developed where analyte
binding to nanostructure surface-bound receptors results in an
increase in refractive index and consequently a LSPR peak
shift.35,36 In this context, it has not been possible to detect and
quantify sequence speciﬁc miRs by their direct hybridization to
nanostructure probes followed by monitoring the LSPR
properties of nanostructures without using labeling steps. We
now report for the ﬁrst time the fabrication of label-free, solid-
state plasmonic biosensors for miR detection. The biosensing
involves the direct hybridization of PDAC-relevant miRs in
plasma to their complementary single-stranded DNAs (HS-C6-
ssDNA) that were functionalized on the surface of gold
nanoprisms attached onto a glass substrate. This construct
serves as a plasmonic biosensor through monitoring the LSPR
dipole peak (λLSPR). We also demonstrate that our sensors are
extremely speciﬁc in miR detection and that addition of DNA-
RNA duplex cleaving enzymes regenerates the sensor, allowing
for multiple uses without compromising sensing eﬃciency.
Fabrication of the Plasmonic Biosensor for miRs
Detection. Figure 1 represents the schematic diagram of our
solid-state, label-free plasmonic biosensor fabrication for miR
detection. Chemically synthesized gold nanoprisms (Figure 1a),
which displayed their λLSPR at ∼797 nm upon attachment to
solid substrate immersed in PBS buﬀer, were selected as
nanoantennas for our biosensor fabrication because (1) their
λLSPR peak position (in the 700−900 nm wavelength range) is
particularly suitable for biomolecule detection because of
Figure 1. Design of plasmonic biosensors and detecting miR-X in various physiological media. (a) Chemically synthesized and freshly prepared gold
nanoprisms were covalently attached onto a 3-mercaptopropyltriethoxysilane-functionalized glass coverslip (substrate). (b) Surface of gold
nanoprisms was chemically modiﬁed with a 1.0 μM 1:1 mixture of SH-C6-ssDNA-X and PEG6-SH in PBS buﬀer (pH 7.4) to prepare the plasmonic
biosensor. (c) Incubation of sensor in miR-X solution and formation of DNA duplex. (d) Schematic of the extinction spectrum of the biosensor
collected in PBS buﬀer after modiﬁcation with a 1.0 μM 1:1 mixture of SH-C6-ssDNA-X and PEG6-SH (blue curve). The extinction spectrum was
again collected after incubation in miR-X solution and careful rinsing with PBS buﬀer to determine the new peak position (red curve). The extent of
LSPR dipole peak shift (ΔλLSPR) depends on the concentration of miR-X used during the incubation in (c), which ranged from 100 nM to 50 fM. (e)
Plot of ΔλLSPR versus log of miR-X concentrations used to determine the limit of detection. The image is not to scale.
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negligible background scattering and adsorption of endoge-
neous chromophores from physiological media such as blood
and plasma;37,38 (2) they have strong electromagnetic (EM)
ﬁeld enhancement at the sharp tips;39,40 (3) they exhibits a
strong LSPR response to small changes in their surrounding
environment;36,41−46 (4) their atomically smooth surface allows
formation of a self-assembled monolayer (SAM)47 of receptors
with both a tightly packed lower layer of alkylthiols and a more
loosely packed upper layer that provide the required space for
duplex formation with complementary miR strands; (5) gold is
nontoxic and stable under extreme physiological conditions;48
and (6) the gold−sulfur bond is very stable with thiol-modiﬁed
receptors making a strong covalent bond with the gold surface.
Details describing the synthesis of gold nanoprisms and their
attachment onto the silanized glass substrate are provided in
Supporting Information. Recently,49 we have shown that a
molecular sensor fabricated using an ∼35 nm average edge-
length gold nanoprisms displayed an unprecedentedly large 21
nm reversible shift upon a minor 0.6 nm increase in the
thickness of the local dielectric environment. Therefore, gold
nanoprisms of this size and geometry are unique and should
provide extremely high sensitivity if plasmonic biosensors are
fabricated using them, which is the scope of this Letter. This
Letter provides the ﬁrst example of LSPR-based miRs sensing
in physiological media.
For detection and quantiﬁcation, our targets were miR-21
and miR-10b, because we have shown by locked nuclei acid−
based in situ hybridization that they are overexpressed in
pancreatic cells (PCCs) within the tumor mass50,51 and that
circulating miR-10b may serve as biomarker for diagnosis of
PDAC.8 We designed the sensing strategy based on the
hybridization between complementary probes (-C6-ssDNA-X,
X = 21 and 10b) attached to gold nanoprisms and their target
miRs. The introduction of spacers in-between the DNA probes
was included to reduce steric hindrance between the probes
and the miRs and therefore to enhance the hybridization and
ultimately the sensitivity. As shown in Figure 1b, poly(ethylene
glycol)6-thiols (PEG6-SH) were used as spacers because they
avoid nonspeciﬁc adsorption of extraneous materials onto the
nanoprism’s surface and are not reactive toward miRs or other
biological constituents present in plasma. Previously, we
demonstrated that functionalization of a nanoantenna’s surface
with an equal mole ratio of receptor and spacer provided the
best sensitivity and lowest limit of detection (LOD).42
Therefore, a 1:1 ratio of HS−C6-ssDNA-X:PEG6-SH was
used to prepare the plasmonic biosensors (Figure 1b). All the
miRs and oligonucleotides sequences used in these studies are
provided in Supporting Information, Table S1.
As illustrated in Figure 2a, we used UV−vis spectroscopy to
monitor the changes in λLSPR of the gold nanoprisms at
diﬀerent functionalization steps. The functionalization of
Figure 2. MicroRNA detection using label-free plasmonic biosensors. (a) Monitoring LSPR dipole peak (λLSPR) changes by UV−visible absorption
spectra of gold nanoprisms during various functionalization steps: before (black, λLSPR = 800 nm) and after functionalized with a 1 μM/1 μM ratio of
HS-C6-ssDNA-21/PEG6-SH (red, λLSPR = 821 nm), and after incubation with 100 nM miR-21 solution in PBS buﬀer (blue, λLSPR = 839 nm). (b)
average λLSPR peak shift (ΔλLSPR) of gold nanoprisms functionalized with a 1 μM/1 μM ratio of HS-C6-ssDNA-21/PEG6-SH after incubation in
diﬀerent concentrations of miR-21 in PBS buﬀer (red triangles), 40% human plasma (black squares), and 40% bovine plasma (blue diamonds). The
ΔλLSPR were calculated by taking the diﬀerence between the λLSPR peak position of the plasmonic biosensor after and before the hybridization with
miR-21 in the various media. (c) Average ΔλLSPR of the plasmonic biosensor functionalized with a 1 μM/1 μM ratio of HS-C6-ssDNA-10b/PEG6-
SH after hybridization with diﬀerent miR-10b concentrations in PBS buﬀer (red triangles), in 40% human plasma (black squares), and in 40% bovine
plasma (blue diamonds). All extinction spectra recorded after miR-X incubation were measured in PBS buﬀer after rinsing with PBS buﬀer.
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substrate-bound nanoprisms with 1:1 ratio of HS−C6-ssDNA-
21:PEG6-SH resulted in an ∼20.5 ± 3.2 nm red-shift of λLSPR as
a result of the increase in local refractive index, which suggested
the attachment of both molecular species onto the nanoprism’s
surface. These plasmonic biosensors were utilized for miR
detection by incubating miR-21 (obtained from Sigma-Aldrich,
U.S.A.) with concentration ranging from 100 nM to 50 fM in
PBS buﬀer, 40% bovine plasma, or 40% human plasma. The
λLSPR response of gold nanoprisms for each miR-21
concentration was measured where the highest 18.8 ± 1.9
nm λLSPR red shift was observed for 100 nM miR-21 (Figure 2a,
blue) in PBS buﬀer. We hypothesize that the λLSPR red-shift is
due to hybridization between ssDNA-21 and miR-21. It was
found that the magnitude of the λLSPR shift was concentration
dependent, where 50 fM miR-21 caused a 3.7 ± 0.3 nm λLSPR
red shift in PBS buﬀer. Figure 2b illustrates the magnitude of
the λLSPR shift (ΔλLSPR) upon DNA/RNA duplex formation for
various miR-21 concentrations in the three diﬀerent media.
Evidently higher concentrations of miR-21 induced a larger
number of ssDNA-21 strands to convert to DNA/RNA
duplexes and consequently a larger change in the local
refractive index around the nanoprisms, which results in a
larger value of ΔλLSPR.
The highest red shift of 18.8 ± 1.9 nm we observed for 100
nM miR-21 incubation with our plasmonic biosensor is
signiﬁcant considering only an ∼5% change in the refractive
index upon ssDNA/RNA duplex formation.52 We believe such
a high sensitivity of our plasmonic biosensors is because of the
unique LSPR properties of our gold nanoprisms and the
possibility of electron delocalization as the ssDNA forms the
duplex and becomes double-strand. The atomically ﬂat surface,
extremely small height (∼8 nm), and sharp tips of our
nanoprisms display strong EM ﬁeld enhancement near their
surface and therefore are expected to be extremely sensitive to
small changes of their local dielectric environment.35,40
Moreover, transformation of ssDNA into double-strand DNA
signiﬁcantly changes the refractive index because of the high
charge density and polarizability of the DNAs.52 The duplex
DNA is capable of long-range charge transfer and alters the
electron density around the nanoprisms thus inﬂuencing their
LSPR properties. This interesting phenomenon requires further
scientiﬁc study, which is currently under our investigation.
Our sensing mechanism is based on the hypothesis that the
attachment of complementary target miRs to our plasmonic
biosensor will shift the λLSPR to higher wavelength (Figure 1c).
The total shift (ΔλLSPR) depended on the miR concentration
(Figure 1d) and could be used to determine the limit of
detection (LOD) (Figure 1e). The LODs calculated for miR-21
in three diﬀerent media were found to be in the range of 23−35
fM, which was more than 1000 and 3 fold lower than with the
label-free microring resonator (150 fmol)15 and the nanopore
based (100 fM)16 miR sensors, respectively. Importantly, these
techniques detected miRs in PBS buﬀer whereas we have
demonstrated here for the ﬁrst time a sensing approach in
physiological media. Utilizing our same direct hybridization-
based detection approach, plasmonic biosensors were con-
structed with of −C6-ssDNA-10, while keeping other
parameters constant. The LOD for miR-10b in the above
media was determined over a concentration range from 100 nM
to 50 fM. The average ΔλLSPR and LODs for miR-10b in three
diverse media are shown in Figure 2c.
The principle underlying the actions of plasmonic biosensors
is based on the successful hybridization between miRs and
ssDNA attached to nanoprisms, where a higher number of
duplex formations will result in a larger change in the refractive
index surrounding the nanoprisms resulting in larger ΔλLSPR
and higher sensitivity. Therefore, it would be expected that
functionalization of gold nanoprisms with 100% HS−C6-
ssDNA-X (without the PEG6-thiol spacer) should reduce the
LOD values because of steric hindrance and low attachment of
miRs. To investigate this, gold nanoprisms were functionalized
with 100% −C6-ssDNA-21 resulting in an ∼15.0 ± 1.8 nm
λLSPR red shift (Figure 3a). The sensor was then incubated in
diﬀerent concentrations of miR-21 prepared in 40% human
plasma. As illustrated in Figure 3a, an ∼9.6 ± 1.1 nm red shift
was observed for a 100 nM miR-21 concentrations and the
lowest concentration that can be repeatedly detected was 10
pM from a ΔλLSPR of 3.4 ± 0.5 nm. Figure 3b shows the ΔλLSPR
versus concentration plot. Evidently, functionalization of the
nanoprism’s surface with 100% −C6-ssDNA-21 resulted in a
200-fold increase in detection limit in comparison to the 1:1
ratio −C6-ssDNA-21/PEG6-SH mixed functionalization (Sup-
porting Information Table S2). These experimental data further
highlight our rationale for using spacers that increase the
likelihood of hybridization. We believe fully covered gold
nanoprisms were obtained when 100% −C6-ssDNA-21 was
Figure 3. Determining the optimum detection condition. (a) UV−
visible extinction spectra monitoring the LSPR dipole peak (λLSPR) of
gold nanoprisms attached to silanized glass substrate before (black,
λLSPR = 796 nm) and after (red, λLSPR = 811 nm) functionalization with
1 μM of HS-C6-ssDNA-21 without PEG6-SH spacers and after
incubation in 100 nM miR-21 solution in 40% human plasma (blue,
λLSPR = 822 nm). (b) Average ΔλLSPR of these HS-C6-ssDNA-21
functionalized gold nanoprisms upon hybridization with diﬀerent miR-
21 concentrations in 40% human plasma. The ΔλLSPR were calculated
by taking the diﬀerence between the λLSPR peak position of the
nanoprisms after and before the incubation with miR-21 in PBS buﬀer.
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used for functionalization, which creates steric hindrance and
does not allow the maximum number of miR-21 strands to
come into close proximity with −C6-ssDNA-21 for hybrid-
ization. Therefore, not all the −C6-ssDNA-21 attached on the
gold nanoprisms’ surface was hybridized with miR-21 strands
resulting in low sensing response. Thus, if we introduce a
spacer between the −C6-ssDNA-21, it will allow the maximum
-ssDNA-21 strands to be freely available for hybridization
without any interference and ultimately enhance the sensitivity
of the biosensor. Accordingly, for the remaining of our
investigation, we used a 1:1 mixed −C6-ssDNA-X:PEG6-SH
to functionalize the gold nanoprisms.
In order to conﬁrm the hybridization of miR-X with −C6-
ssDNA-X that resulted in the ΔλLSPR, the enzyme RNase H was
used to selectively cleave the DNA: RNA duplex and
potentially reverse the ΔλLSPR. Initially, the plasmonic biosensor
for miR-21 was incubated in a 100 nM solution of miR-21,
which resulted in red-shift of λLSPR potentially reﬂecting
hybridization. The biosensor was then immersed in 15 units
of RNase H solution for 2 h. Afterward the λLSPR showed a blue
shift and reverted back to its original position before miR-21
incubation (Figure 4a). When the 1:1 ratio −C6-ssDNA-
21:PEG6-SH mixed functionalized biosensor was incubated
with RNase H solution alone overnight, no noticeable change
in λLSPR value was observed (Supporting Information Figure
S7). These experimental results validate our previous
observation that the λLSPR blue shift was due to the cleavage
of heteroduplex done by RNase H. The biosensors were rinsed
with RNase free water to PBS buﬀer and again incubated in 100
nM miR-21 solution for rehybridization where an ∼14 nm red
shift of the λLSPR was observed. These experiments conﬁrm our
working hypothesis that hybridization between the nanoprism’s
surface ligands (−C6-ssDNA-X) and the miR-X resulted in
changes in the local dielectric environment around the
nanoprisms causing wavelength shift. As shown in Figure 4b,
the λLSPR responses were identical for several cycles due to
hybridization and dehybridization of miR-21 over a period of 6
days. The same experiments were done for the miR-10b
biosensor and similar results were observed, underscoring the
long-term stability of the sensors and their potential for being
developed into cost-eﬀective point of care diagnostic tools.
The hybridization takes place at the 5′ end of −C6-ssDNA-
21 and the 3′ end of miR-21, which evidently increased the
refractive index. Additionally such hybridization would also
increase the thickness of the local dielectric environment of the
nanoprisms. Together, a signiﬁcantly large ΔλLSPR was
generated for both miR-21 and miR-10b. Atomic force
microscopy (AFM) analysis was conducted to characterize
our plasmonic biosensors and also to verify the change in
surface area caused by miR-21 incubation with mixed −C6-
ssDNA-21 and PEG6-SH-functioanlized gold nanoprisms. After
analyzing 40 diﬀerent nanoprisms (Figure 5 and Supporting
Information Figure S8) − the exact same area of four diﬀerent
sections of the sensor - an average 2.4 × 10−15 m2 increase in
surface area was observed by AFM. Thus, attachment of miRs
to plasmonic biosensors has increased the thickness of local
dielectric environment around the gold nanoprisms and
inﬂuenced their LSPR properties. Ultrasensitive refractive
index-induced LSPR response of nanoprisms allows us to
fabricate label-free plasmonic biosensor.
The successful implementation of plasmonic biosensors for
use with real biological samples mandates documentation of
their speciﬁcity toward target miRs in that patient samples
containing multiple miR species. The mix functionalized (−C6-
ssDNA-21 and PEG6-SH) biosensors were incubated overnight
in 40% human plasma solution containing 100 nM each of
miR-16, miR-122, miR-126, and miR-141 because these miRs
are commonly present in human plasma. The λLSPR response
was measured before and after incubation (Supporting
Information Figure S9) and resulted in an ∼2.5 ± 0.3 nm
λLSPR red shift, which is within the instrument noise level and/
or minor nonspeciﬁc adsorption of extraneous materials present
in human plasma. In another control experiment, gold
nanoprisms attached as before to glass substrate were
functionalized with 100% PEG6-SH by incubation in a 1 μM
aqueous solution, and after rinsing with large amounts of water,
incubated in a 40% human plasma solution of 100 nM miR-21
for 12 h. This procedure resulted in only an ∼0.9 ± 0.7 nm
λLSPR red shift (Supporting Information Figure S10),
conﬁrming that the plasmonic biosensors we designed are
highly speciﬁc toward the target miRs.
Detection of miR Levels in in Plasma from Pancreatic
Cancer Patients. Pancreatic cancer is the fourth-leading cause
Figure 4. Characterization of the plasmonic biosensors regeneration
ability. (a) UV−visible extinction spectra of gold nanoprisms
functionalized with a 1 μM/1 μM ratio of HS-C6-ssDNA-21/PEG6-
SH (red, λLSPR = 818 nm) attached to silanized glass, after incubation
with 100 nM of miR-21 (blue, λLSPR = 832 nm), after treatment with
15 units of RNase H for 2 h (red dotted, λLSPR = 818 nm), and after
rehybridized with 100 nM of miR-21 (blue dotted, λLSPR = 832 nm).
(b) Changes in LSPR dipole peak position (λLSPR) of gold nanoprisms
functionalized with a 1 μM/1 μM ratio of HS-C6-ssDNA-21/PEG6-
SH upon hybridization and dehybridization with miR-21 for several
cycles. The λLSPR peak shifts back and forth upon sensor regeneration
with RNase H by cleaving DNA/RNA duplex and rehybridization after
incubation into 100 nM miR-21 in 40% human plasma. After each of
the dehybridization steps, the plasmonic biosensors were thoroughly
rinsed with PBS buﬀer to completely remove enzyme RNase H.
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of cancer death in the United States with an annual mortality of
nearly 40 000 and a dismal ﬁve-year survival rate of 6%.1 PDAC
is characterized by chemotherapeutic resistance and by the
absence of an eﬀective screening procedure for early disease. It
is generally accepted that early diagnosis could reduce mortality
rates substantially and thus a noninvasive early PDAC test must
be developed. Several miRs (such as miR-21, -10b, -103, -155,
-196a, 210, and -221) were found to be overexpressed in
PDAC.6−8,53 Given their resistance to degradation, plasma
miRs have the potential to serve as biomarkers for the
noninvasive diagnosis of PDAC. Previously, nanopore sensors
were used to detect miRs in lung cancer patients, but to the
best of our knowledge no sensors have been developed to date
to detect PDAC-related miRs in human plasma.
Utilizing our plasmonic biosensors we detected miR-21 and
miR-10b in plasma from PDAC patients. Plasma samples were
collected from six patients and six normal control subjects.
Total plasma RNAs including miRs were extracted from 100 μL
of each plasma sample using a TRIZOL kit with a ﬁnal elution
volume of 28 μL. Next, 14 μL volumes were used for miR
quantiﬁcation by the plasmonic biosensor and the remaining 14
μL were used in the qRT-PCR assay. The plasmonic biosensors
were fabricated as described before for both miR-21 and miR-
10b detection. The extracted human miR-21 or miR-10b
samples were diluted in PBS buﬀer and incubated with the
biosensors were for 12 h, followed by rinsing with PBS buﬀer
and measurement of the λLSPR response in PBS buﬀer. The
observed λLSPR shift for each miR-21 and miR-10b sample was
converted into the corresponding concentration using the
calibration curve derived for miR-21 or 10b under optimized
conditions and compared with the value from normal control
subjects (Figure 6a,c). The concentrations of miR-21 and miR-
10b determined from plasmonic biosensors were also compared
with the values obtained from the qRT-PCR assay (Figure 6b
and Supporting Information Figure S16). Importantly, for the
ﬁrst time through a label-free technique we have shown that
miR-10b concentration is nearly 4-fold higher than the miR-21
level in patient samples. Inasmuch as both miR-21 and miR-10b
are overexpressed in PDAC, it is possible that miR-10b is
released more eﬃciently by pancreatic cancer cells than miR-21,
allowing it to achieve higher levels in the circulation. It is
therefore possible that miR-10b levels are also increased within
the pancreatic tumor microenvironment, where it could be
acting to enhance PDAC biological aggressiveness.
We also detected miR-21 levels directly in human plasma
samples collected from PDAC patients without RNAs
extraction. Thus, human plasma (50 μL/sample) from six
pancreatic cancer patients were diluted in PBS buﬀer followed
by incubation with our plasmonic biosensors for 12 h. The
λLSPR response of each sample was measured through UV−vis
spectroscopy and showed a steady increase in concentration
from sample 6 to 1 (Figure 6d). Both plasmonic biosensor and
qRT-PCR results indicated that miR-10b levels were higher in
PDAC patients compared to normal control subjects and that
the levels of miR-21 and miR-10b can be quantiﬁed with high
accuracy using our gold nanoprism-based plasmonic biosensor
Figure 5. Surface characterization of the plasmonic biosensors. Atomic force microscopy images of gold nanoprisms bound to silanized glass
substrate (a) after functionalization with 1:1 ratio of HS-C6-ssDNA-21/PEG6-SH (b) and after hybridization with100 nM miR-21 in 40% human
plasma (c). The measurements were conducted in air. (d) Changes in the surface area of gold nanoprisms after each functionalization steps. Forty
nanoprisms were selected to determine the average change in the surface area. Detailed method of surface area calculation is provided in the
Supporting Information ﬁle.
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without any modiﬁcation, ampliﬁcation, or labeling. Impor-
tantly, the miR-21 concentration in extracted samples was at
least 2-fold lower than in the pure plasma samples. We believe
this is due to loss of miRs during the RNA extraction process,
which requires multiple steps for RNA puriﬁcation. Therefore,
the most widely used qRT-PCR method to determine the
concentration of miRs in patients may not accurately represent
the actual concentration. This limitation and imprecise
quantiﬁcation can be avoided by using our newly developed
plasmonic biosensors, which can provide a unique opportunity
as potential diagnostic and prognostic markers in PDAC, other
cancers, and potentially other disease states.
Conclusion. We have designed, fabricated, and charac-
terized a plasmonic biosensor that was able to detect PDAC
relevant miRs in human plasma without using RNAs extraction,
which opens a new avenue for the direct detection and
quantiﬁcation of miR levels in clinical samples without any
form of sample preparation. To our knowledge, this is the ﬁrst
LSPR-based, label-free, direct hybridization method for miR
detection, which eliminates all the current drawbacks such as
labeling, tagging, ampliﬁcation, use of highly toxic chemical, and
further modiﬁcation of the sensor. Furthermore, it vastly
simpliﬁes the detection approach without requiring detailed
knowledge of the electron or energy transfer processes involved
as in other more complicated techniques. Additionally, this
ultrasensitive, plasmonic-based, direct hybridization-controlled
detection approach is applicable to any type of miRs that are
relevant to various diseases. It was found that our plasmonic
biosensor can be regenerated through several cycles and is
stable for several days without compromising its sensitivity and
selectivity, which should enable the development of simple,
cost-eﬀective tools for the early detection of miRs and thus
facilitate the early diagnosis of various cancers. Finally, the large
EM-ﬁeld enhancement at the nanoprism’s sharp tips39 will
enhance the Raman scattering intensity of the analytes. In
theory, therefore, nanoprisms can be used to design eﬀective
substrates for surface-enhanced Raman spectroscopy-
based54−57 detection and quantiﬁcation of multiple miRs
simultaneously through integration of their spectral character-
istic with the λLSPR shifts.
Materials and Methods. All synthetic DNA probes and
microRNAs were purchased from Sigma-Aldrich (U.S.A.). PBS
buﬀer prepared with RNase-free water was used to dilute
oligonucleotides and miRs solutions. Patient plasma was
obtained from the Indiana University Simon Cancer Center
Solid Tissue Bank (Indianapolis, Indiana).
Fabrication of LSPR-Based miR Sensors and Detection.
The gold nanoprism-based miR sensors were designed using
our published procedure with modiﬁcation.49 The attachment
of gold nanoprisms on silanized glass substrates is described in
the Supporting Information ﬁle. The substrate-bound nano-
prisms were incubated in PBS buﬀer solution containing 1 μM
each of HS−C6-ssDNA-X and PEG6-SH overnight and rinsed
with PBS buﬀer. The initial LSPR peak position of each sensing
platform was determined using UV−visible spectroscopy in
PBS buﬀer and then was incubated in the diﬀerent
concentrations of miR solutions, for exmaple, either in PBS
buﬀer, 40% bovine plasma, or 40% human plasma for 12 h at
Figure 6. Determination of microRNA concentration in PDAC patients and normal control subjects. (a) The average λLSPR peak shifts of gold
nanoprisms functionalized with a 1:1 ratio of HS-C6-ssDNA-21/PEG6-SH upon hybridization with miR-21 from the total RNAs extracted from
plasma samples of PDAC patients (blue diamonds) and normal control subjects (blue squares). The respective λLSPR peak shifts were converted to
concentrations using the calibration curve established for miR-21 in PBS buﬀer as shown in Figure 2b [PDAC patients (red triangles), and for
normal control subjects (red circles)]. (b) Comparison of miR-21 concentration for six PDAC patients determined using plasmonic biosensors (blue
diamond) and qRT-PCR (red square). (c) Similar experiments were conducted to detect miR-10b where the λLSPR peak shifts and concentrations for
PDAC patients are shown in blue diamonds and red triangles, respectively. The λLSPR peak shifts (blue squares) and concentrations (red circles) for
normal controls are shown for comparison. (d) The average λLSPR peak shifts (blue diamonds) and concentration (red triangles) for the miR-21 in
plasma samples from PDAC patients without any puriﬁcation.
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room temperature. The plasmonic biosensors were thoroughly
washed with PBS buﬀer to remove any nonspeciﬁcally adsorbed
species. The miR bound biosensor was then placed in PBS
buﬀer for 10 min before the LSPR peak position was
determined. For UV−vis extinction spectra measurement, one
particular solvent was chosen to avoid the solvent dielectric
constant eﬀect, which is known to shift the LSPR peak.21,58,59
Total RNA Extraction and Quantiﬁcation of MicroRNA by
qRT-PCR. Total RNA was isolated from plasma samples that
were obtained from the Indiana University Simon Cancer
Center Solid Tissue Bank (Indianapolis, IN, U.S.A.) using
Trizol-LS reagent (Life Technologies, Carlsbad, CA, U.S.A.).
cDNA was generated using 10 ng of RNA and miR-10b, miR-
21, or miR-425−5p RT primers and a miR reverse transcription
kit (Life Technologies) as per the manufacturer’s recommen-
dations. Quantitative PCR (qPCR) was performed using
Taqman miR expression assay reagents. Expression levels as
determined by qPCR were normalized to miR-425-5p, since
this miR was expressed at similar levels in all samples and
exhibited <1 cycle threshold (Ct) diﬀerence across all samples.
After normalization to miR-425-5p (ΔCt), the ΔCt values for
miRs in controls were averaged and subtracted from the ΔCt
values of each individual sample (ΔΔCt). miR levels were then
calculated using the 2−ΔΔCt method.60
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